Doubts cast on AXA North
Research house Adviser Edge has warned that the popular AXA North product may have been oversold, saying many of the investment options offered in the product have a low chance of relative investment success.
Adviser Edge said the merits of the investment vary depending on the choice of term and asset allocation used in the strategy. The research house said that while a 10-year term with the most conservative strategy achieved a four star rating, all other combinations were rating as 3.5 or 3.75 stars.
According to researcher Geoff Watkins, quantitative testing of AXA North suggests it has been oversold.
“Overall quantitative results modelling indicated that only very long and/or strong bull markets give rise to performance that is better than that of a simple fixed interest fund,” the research house said.
“The combination of shorter-term cycles in the equity market and ongoing annual fees in the AXA North product depressed returns over long periods, particularly for the 15 and 20-year alternatives.
Furthermore, Adviser Edge found that the five to seven-year guarantee alternatives rarely provide value to an investor, yet require the annual fees to be paid for the full term.”
Recommended for you
There is a gap in the market for Australian advisers to help individuals with succession planning as the country has been noted by Capital Group for being overly “hands off” around inheritances.
ASIC has cancelled the AFSL of an advice firm associated with Shield and First Guardian collapses, and permanently banned its responsible manager.
Having peaked at more than 40 per cent growth since the first M&A bid, Insignia Financial shares have returned to earth six months later as the company awaits a final decision from CC Capital.
Private market secondaries manager Coller Capital has unveiled a new education platform to improve advisers’ and investors’ understanding of secondaries.
